药学学报, 2019, 54(11): 2069-2073
引用本文:
马雨璇, 王娜, 戴苏云, 王冰, 李钢. 抗凝药利伐沙班的制备与表征[J]. 药学学报, 2019, 54(11): 2069-2073.
MA Yu-xuan, WANG Na, DAI Su-yun, WANG Bing, LI Gang. Preparation and characterization of rivaroxaban as an anticoagulant[J]. Acta Pharmaceutica Sinica, 2019, 54(11): 2069-2073.

抗凝药利伐沙班的制备与表征
马雨璇, 王娜, 戴苏云, 王冰, 李钢
南京师范大学生命科学学院, 分析测试中心,江苏 南京 210023
摘要:
以抗凝药利伐沙班晶型Ⅰ为基础,通过重结晶的方法对其进行多晶型的制备,确定了两种晶型Ⅱ(药用晶型)、五种晶型Ⅳ的制备方法。采用X射线粉末衍射(PXRD)、差示扫描量热仪(DSC)、元素分析(EA)、质谱(MS)和红外光谱(IR)等现代分析手段对制备的晶型进行了定性并且通过扫描电子显微镜(SEM)观察了不同晶型的形貌。结果表明,本方法所制备的晶型Ⅱ和Ⅳ的PXRD与DSC分析结果与国内外专利一致,EA、MS和IR的检测结果符合利伐沙班的化学结构,由SEM可知晶型Ⅰ呈片层状,晶型Ⅱ呈线状,晶型Ⅳ呈条状。综上,与国内外专利相比,本研究制备晶型Ⅱ和Ⅳ的方法可靠,所需试剂易得,实验条件易实现,制备过程简捷。本研究为利伐沙班的生产应用提供了新的参考。
关键词:    利伐沙班      多晶型      X射线粉末衍射      定性分析     
Preparation and characterization of rivaroxaban as an anticoagulant
MA Yu-xuan, WANG Na, DAI Su-yun, WANG Bing, LI Gang
School of Life Sciences, Test and Analysis Center, Nanjing Normal University, Nanjing 210023, China
Abstract:
The preparation of polymorphic forms of rivaroxaban was carried out using a recrystallization method based on that for crystal form-Ⅰ. Preparation methods were developed for two crystal forms-Ⅱ (medicinal crystal form) and five crystal forms-Ⅳ and the crystals were then characterized. The crystalline form was identified by applying modern analytical means including X-ray powder diffraction (PXRD), differential scanning calorimetry (DSC), element analysis (EA), mass spectrometry (MS), and infrared spectrum (IR), and the morphology of different crystal forms was observed by scanning electron microscopy (SEM). The results show that the PXRD and DSC characteristics of prepared crystal forms-II and IV are consistent with those described in patents at home and abroad, and the test results with EA, MS and IR are in accordance with the chemical structure of rivaroxaban. The crystal form-I is lamellar, the crystal form-II is linear and crystalline form-IV is striped as determined by SEM. In summary, the methods for preparing crystal form-II and form-IV are reliable, the required reagents are easily available, the experimental conditions are easy to implement and the preparation process is simple. Our study provides a new reference for the production and application of rivaroxaban.
Key words:    rivaroxaban    polycrystalline form    X-ray powder diffraction    qualitative analysis   
收稿日期: 2019-06-09
DOI: 10.16438/j.0513-4870.2019-0363
基金项目: 江苏省大型科学仪器设备共享服务平台资助(BZ201403).
相关功能
PDF(393KB) Free
打印本文
0
作者相关文章
马雨璇  在本刊中的所有文章
王娜  在本刊中的所有文章
戴苏云  在本刊中的所有文章
王冰  在本刊中的所有文章
李钢  在本刊中的所有文章

参考文献:
[1] Wang LD, Liu JM, Yang G, et al. Prevention and treatment of stroke in China is still facing enormous challenges-summary of 2018 report on stroke prevention and treatment in China[J]. Chin J Circ (中国循环杂志), 2019, 34: 105-119.
[2] Liu L, Liu J. A study on self-reflection and insight level and characteristics of schizophrenic and depression patients[J]. Chin J Behav Med Brain Sci (中华行为医学与脑科学杂志), 2018, 27: 31-34.
[3] Wu WY. Development of antidepressants and application of fluoxetines[J]. Chin J Ment Health (中国心理卫生杂志), 2017, 31(z2): 3.
[4] Jiang LH, Huang JL, Chen LH. Efficacy and safety of rivaroxaban in anticoagulant treatment of patients with non-valvular atrial fibrillation[J]. Eval Anal Drug-Use Hosp China (中国医院用药评价与分析), 2019, 19: 304-305, 308.
[5] Liu W, Dong JH. Rivaroxaban[J]. Chin J Pharm Chem (中国药物化学杂志), 2011, 21: 508, 510.
[6] Yin XH, Zhang QG, Zhang XS, et al. Analysis of influencing factors and prevention and treatment of deep venous thrombosis of lower limb after arthroplasty of lower extremities[J]. China Pharm (中国药业), 2014, 23: 30-33.
[7] Huang BY, Zeng WQ, Tan GL, et al. Cost-effectiveness analysis of rivaroxaban and warfarin in the prevention of stroke in patients with non-valvular atrial fibrillation[J]. Chin J Clin Ration Drug Use (临床合理用药杂志), 2019, 12: 57-58.
[8] Zhou J, Liu ZD, Lin WL. Efficacy and safety of rivastatin in the prevention of deep venous thrombosis of lower extremities after hip arthroplasty[J]. Chin J Clin Pharm (中国临床药理学杂志), 2015, 31: 1106-1108.
[9] Zhao YN, Chen XQ, Zhu K, et al. Thermostability and crystal structure of anticancer drug dasatinib[J]. Acta Pharm Sin (药学学报), 2011, 46: 1104-1107.
[10] Huang R, Wang T, Yang X, et al. Characterization of taste-masking dry emulsion of azithromycin by in vitro and in vivo evaluation[J]. Acta Pharm Sin (药学学报), 2017, 52: 795-801.
[11] Li G, Su GQ, Xu QW, et al. A new crystal form of nateglinide[J]. Acta Pharm Sin (药学学报), 2001, 37: 532-534.
[12] Zhang GS, Zhang L, Gong NB, et al. Study on Polycrystalline form of Levaraban[C]. National Symposium on Research and Development of Crystalline Drugs (全国晶型药物研发技术学术研讨会), 2014: 69-73.
[13] Xu Y, Wu S P, Liu X J, et al. Crystal characterization and transformation of the forms I and II of anticoagulant drug rivaroxaban[J]. Crystal Res Technol, 2017, 52: 1600379.
[14] Gao J, Teng ZJ, Shu LH, et al. The transformation of drug crystal form in the production process of solid preparations[J]. Chin J New drugs (中国新药杂志), 2018, 27: 1000-1005.
[15] Bayer intellectual property co., Ltd. Novel polycrystalline and amorphous 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidine-5-yl}-methyl)-2-thiophene carboxylamides: CN, 101282968[P]. 2008-10-08.
[16] Li DX, Ke H, Fan XB, et al. New crystal form and preparation method and use thereof for rivaroxaban: CN 104211693 A[P]. 2014-12-17.
相关文献:
1.李钢;陈家英;吕光烈;徐群为.那格列奈的多晶结构与药效测定[J]. 药学学报, 2005,40(10): 958-960